Real-World study tracks quality of life on new myeloma drug combo
NCT ID NCT05954780
First seen Nov 01, 2025 · Last updated Apr 26, 2026 · Updated 29 times
Summary
This study observes 75 adults with relapsed or refractory multiple myeloma who are already taking selinexor (Nexpovio®) combined with bortezomib and dexamethasone. Researchers track quality of life, side effects, and how well the treatment works in everyday medical practice. The goal is to gather real-world evidence to complement previous clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gemeinschaftspraxis für Hämatologie und Onkologie GbR
Ravensburg, Baden-Wurttemberg, 88212, Germany
-
Medizinische Universität Wien, Universitätsklinik für Innere Medizin I
Vienna, 1090, Austria
Conditions
Explore the condition pages connected to this study.